2 reports

IT IS HOPED THAT THE INCREASED UNDERSTANDING OF HCC' S PATHOLOGY WILL HELP TO IDENTIFY FURTHER POTENTIAL MOLECULAR TARGETS AS WELL AS HELP DEVELOP BIOMARKERS ABLE TO GUIDE TREATMENT DECISIONS.

  • Hepatitis
  • Pathology
  • World
  • Forecast
  • Onxeo SA

All patients who received at least one dose of belinostat and had a confirmed PTCL diagnosis by the central pathology review were included in the efficacy analysis set.

  • Chemotherapy
  • Pathology
  • Research And Development
  • Therapy
  • Onxeo SA